Literature DB >> 14500967

Medicine. Stroke--tPA and the clinic.

John R Marler1, Larry B Goldstein.   

Abstract

Clinical trial results are not always rapidly incorporated into routine medical practice. This Policy Forum describes a variety of barriers that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator) for selected patients with acute ischemic stroke. These barriers are not insurmountable but will require a concerted effort to overcome.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14500967     DOI： 10.1126/science.1090270

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  19 in total

1.  Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.

Authors:  Mingming Ning; David A Sarracino; Ferdinando S Buonanno; Bryan Krastins; Sherry Chou; David McMullin; Xiaoying Wang; Mary Lopez; Eng H Lo
Journal:  Transl Stroke Res       Date:  2010-12-01       Impact factor: 6.829

2.  Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform.

Authors:  James K T Wang; Stuart Portbury; Mary Beth Thomas; Shawn Barney; Daniel J Ricca; Dexter L Morris; David S Warner; Donald C Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-22       Impact factor: 11.205

3.  Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.

Authors:  Enming J Su; Linda Fredriksson; Melissa Geyer; Erika Folestad; Jacqueline Cale; Johanna Andrae; Yamei Gao; Kristian Pietras; Kris Mann; Manuel Yepes; Dudley K Strickland; Christer Betsholtz; Ulf Eriksson; Daniel A Lawrence
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 4.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

5.  The good and bad of microglia/macrophages: new hope in stroke therapeutics.

Authors:  Ya-chi Huang; Zhong-ping Feng
Journal:  Acta Pharmacol Sin       Date:  2012-12-24       Impact factor: 6.150

6.  Preserving Mitochondrial Structure and Motility Promotes Recovery of White Matter After Ischemia.

Authors:  Chinthasagar Bastian; Jerica Day; Stephen Politano; John Quinn; Sylvain Brunet; Selva Baltan
Journal:  Neuromolecular Med       Date:  2019-05-31       Impact factor: 3.843

7.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

8.  Implications of immune system in stroke for novel therapeutic approaches.

Authors:  Aaron A Hall; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-01-13       Impact factor: 6.829

9.  Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings.

Authors:  Robert Brunkhorst; Waltraud Pfeilschifter; Christian Foerch
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

10.  The spleen contributes to stroke-induced neurodegeneration.

Authors:  Craig T Ajmo; Dionne O L Vernon; Lisa Collier; Aaron A Hall; Svitlana Garbuzova-Davis; Alison Willing; Keith R Pennypacker
Journal:  J Neurosci Res       Date:  2008-08-01       Impact factor: 4.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.